Aurinia Pharmaceuticals Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for patients with rare autoimmune and kidney-related diseases with high unmet medical needs; it markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis, and advances a pipeline including aritinercept (formerly AUR200), a recombinant Fc fusion protein dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) targeting autoimmune conditions such as systemic lupus erythematosus and IgA nephropathy, along with other investigational assets like AUR300 for M2 macrophage modulation in fibrotic and inflammatory diseases. The company maintains a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for voclosporin commercialization in certain regions. Aurinia operates globally with a U.S. commercial hub in Rockville, Maryland, research and development activities worldwide, and serves nephrologists, rheumatologists, and patients in autoimmune disease segments. Founded in 1993 and headquartered at 1203-4464 Markham Street in Victoria, British Columbia, Canada, Aurinia recently reported strong LUPKYNIS net product sales growth of 25% year-over-year to approximately $60 million in the first quarter of 2025, supported by updated American College of Rheumatology guidelines and expanded market access; it completed the acquisition of Thunderbolt Pharma, Inc. in July 2025 to secure aritinercept following positive Phase 1 results demonstrating 48-55% immunoglobulin reduction and favorable safety, with Phase 2 trials planned by year-end in multiple autoimmune indications; the company repurchased 12.2 million shares for $98.2 million, approved an additional $150 million share repurchase program, and held $351.8 million in cash equivalents and investments as of its latest quarterly update.
Company News
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Settles Patent Litigation with Teva
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Playing The Biotech Breakout With Insiders
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates